Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.

Objectives: To compare the effects of a combined oral contraceptive (COC) containing nomegestrol acetate and 17β-oestradiol (NOMAC/E2) on haemostasis, lipids, carbohydrate metabolism, C-reactive protein (CRP) and sex hormone-binding globulin (SHBG) with those of a COC containing levonorgestrel and ethinylestradiol (LNG/EE).

Methods: In a randomised, open-label study, 121 healthy women, 18-50 years of age, were randomly assigned to receive NOMAC/E2 (2.5 mg/1.

Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.

Objectives: To compare the effects of two monophasic combined oral contraceptives, containing either nomegestrol acetate/17β-oestradiol (NOMAC/E2) or levonorgestrel/ ethinylestradiol (LNG/EE) on endocrine function, androgens, and sex hormone-binding globulin (SHBG).

Methods: Randomised, open-label, multi-centre trial involving 121 healthy women, aged 18-50 years old. Participants received NOMAC/E2 (2.

Are recurrent pregnancies a risk in Type 1 diabetes?

Objective: To assess the significance of recurrent pregnancies for the progression of Type 1 diabetes as well as the glycemic level and the occurrence of pre-eclampsia in consecutive pregnancies of the same Type 1 diabetic women.

Methods: A retrospective population-based birth cohort from the years 1986-95, comprising data of all (n = 210) Type 1 diabetic mothers and their 296 births in a geographically defined catchment area. Of the 125 primiparous women, 46 had their first two pregnancies during the study period.